Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
This Month's Featured Content A Fresh IPO That Long-Term Investors Shouldn't IgnoreReported by Jordan Chussler. Published: 1/14/2026. 
Summary - While IPOs are often labeled as high-risk startups, some are worthy of more conservative investors’ attention.
- Aktis Oncology’s IPO—the first biotech IPO of 2026—resulted in a $318 million raise, with the biotech firm receiving $100 million in backing from Big Pharma giant Eli Lilly.
- The company, which now has a market cap of $3.34 billion, develops radiopharmaceuticals and is positioned for long-term success after being listed on the Nasdaq.
For speculative investors, the start of each year is a good time to revisit an initial public offering (IPO) calendar. Almost every week companies go public, and a handful often offer considerable short-term upside potential. Of course, IPOs also carry substantial downside risk. But even conservative investors should not automatically dismiss newly public companies — some can merit a place in buy-and-hold portfolios. One recently public biotechnology company in the healthcare sector could be worth that closer look. Last Year's IPO Success Stories Last year provides a strong example of why newly listed companies shouldn't be dismissed by investors with lower risk tolerances. AI cloud computing provider CoreWeave (NASDAQ: CRWV), which went public in March 2025, is up nearly 123% since then. Short-term speculators may have captured larger early moves (it climbed roughly 359% before 30 days on the Nasdaq), but longer-term holders have still been rewarded. Others, such as Medline (NASDAQ: MDLN), refute the idea that IPOs are only high-risk startups. The medical products and services provider, which debuted publicly in December 2025, was founded in 1966 and already has a market cap above $55 billion. Similarly, Smithfield Foods (NASDAQ: SFD) — famous for its ubiquitous bacon packages — waited 89 years before its IPO. Since going public in January 2025 the stock is up nearly 5% and also pays a dividend that currently yields 4.44%, or $1 per share annually, making it an immediate consideration for income investors. After its IPO and with shares hitting the market on Jan. 9, Aktis Oncology (NASDAQ: AKTS), a maker of radiopharmaceuticals, is hoping for a similar outcome in 2026 and beyond. Why Are Radiopharmaceuticals Important? Aktis Oncology specializes in radiopharmaceuticals — a subset of nuclear medicine that uses radioactive drugs for both diagnostics and treatment of conditions including cancer, heart disease and neurological disorders. Radiopharmaceuticals pair radioactive isotopes with targeting molecules that seek out particular cells (for example, cancer cells) to deliver localized radiation, minimizing damage to healthy tissue compared with less targeted treatments. According to industry consultant Grand View Research, the global nuclear medicine market was estimated at nearly $18 billion in 2024 and is forecast to reach nearly $35 billion by 2030 — a compound annual growth rate of about 10.16%. Importantly for Boston-based Aktis Oncology, Grand View Research notes that North America accounts for nearly 43% of the global nuclear medicine market, with the United States the dominant player. Aktis Oncology's Clinical-Stage Profile Wall Street expects biotech IPO activity to rebound in 2026 after funding cuts in 2025 slowed healthcare listings. Aktis, which debuted on Nasdaq on Jan. 9, was the first biotech IPO of 2026 and produced one of the largest recent raises for a biotech. The company raised $318 million in the IPO and now has a market cap of about $3.34 billion. According to the company's prospectus, the executive team includes drug development, approval and commercialization veterans who have participated in bringing 14 currently FDA-approved products to market. Technically, Aktis develops targeted alpha radiopharmaceuticals — a class of precision cancer drugs that use proprietary technology to attack solid tumors while sparing healthy tissue. The company is clinical-stage and pre-revenue, which is typical for firms at this development phase. Aktis Oncology's Eli Lilly Connection Although Aktis is pre-revenue, that did not prevent the offering from attracting major industry interest. Eli Lilly (NYSE: LLY) anchored the IPO and purchased $100 million of AKTS shares, according to Reuters. That investment builds on a partnership formed in 2024 between Eli Lilly and Aktis to develop tumor-targeting radiopharmaceuticals. Under that deal, Aktis received $60 million in cash and an equity investment from Eli Lilly, with potential milestone payments exceeding $1 billion. The significance of Eli Lilly's backing is notable. At about $1.01 trillion, Lilly is one of the largest Big Pharma companies by market cap after net income jumped substantially from 2023 to 2024. Between its equity stake and the recent $100 million share purchase, the maker of Zepbound has a sizable financial interest in Aktis' success.
| 
